Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

Blood

Volumn 119, Issue 25, 2012, Pages 5989-5995

  Patel, Vivek L ^a   Mahévas, Matthieu ^b   Lee, Soo Y ^a   Stasi, Roberto ^c   Cunningham Rundles, Susanna ^a   Godeau, Bertrand ^b   Kanter, Julie ^d   Neufeld, Ellis ^e   Taube, Tillmann ^f   Ramenghi, Ugo ^g   Shenoy, Shalini ^d   Ward, Mary J ^a   Mihatov, Nino ^a   Patel, Vinay L ^a   Bierling, Philippe ^b   Lesser, Martin ^h   Cooper, Nichola ⁱ   Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF TURIN   (Italy)

^h FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

ⁱ HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CHILD; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPHENOTYPING; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SCHOOL CHILD; SEX RATIO; SINGLE DRUG DOSE; SPLENECTOMY; SUSTAINED RESPONSE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84862739912     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-393975     Document Type: Article

References (52)

1. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B-cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711-717.
2. Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem. 1989;264(19):11282-11287. (Pubitemid 19168862)
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
4. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639-2642.
5. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal anti-body treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005; 78(4):275-280. (Pubitemid 40471119)
6. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-239. (Pubitemid 38534976)
7. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal anti-body rituximab: a pilot study. Eur J Haematol. 2002;69(2):95-100. (Pubitemid 35178108)
8. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol. 2003;74(4):263-267. (Pubitemid 37484695)
9. Penalver FJ, Jimenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85(6):400-406.
10. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27(6):99-103. (Pubitemid 32164602)
11. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005;90(9):1273-1274. (Pubitemid 41375288)
12. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78(11):1340-1346. (Pubitemid 37337779)
13. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005(2);146:217-221. (Pubitemid 40202812)
14. Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica. 2003;88(5):538-546. (Pubitemid 36648443)
15. Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol. 2009;88(3):239-243.
16. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: longterm follow up results. Eur J Haematol. 2008;81(3):165-169.
17. Mueller BU, Bennett CM, Feldman HA, et al. One year follow up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52(2):259-262.
18. Parodi E, Rivetti E, Amendola G, et al. Long-term follow up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144(4):552-558.
19. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46(10):2673-2677. (Pubitemid 36118931)
20. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54(9):2970-2982. (Pubitemid 44497778)
21. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61(10):883-888.
22. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822-825. (Pubitemid 351354792)
23. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
24. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100(9):3426-3428. (Pubitemid 35217098)
25. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74(4):485-489. (Pubitemid 36379372)
26. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol. 2006;125(4):592-597.
27. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura-results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
28. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, et al. Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol. 2007;86(12):871-877.
29. Pasa S, Altintas A, Cil T, et al. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thomb Thrombolysis. 2009;27(3):329-333.
30. Parodi E, Nobili B, Perrotta S, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol. 2006;84(1):48-53. (Pubitemid 44756776)
31. Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90(2):281-283. (Pubitemid 40293304)
32. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
33. Cohen Y, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab. Hematol J. 2002;3(1):61-62. (Pubitemid 34223918)
34. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-2634. (Pubitemid 39434940)
35. Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol. 2003;72(2):94-98. (Pubitemid 36164342)
36. Jansson AF, Wintergerst U, Renner ED, Belohradsky BH. Rituximab-induced long-term remission in two children with SLE. Eur J Pediatr. 2007;166(2):177-181. (Pubitemid 46025511)
37. Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford). 2006;45(12):1505-1513. (Pubitemid 44817056)
38. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B-cell immunotherapy. J Immunol. 2005;174(2):817-826. (Pubitemid 40094277)
39. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930. (Pubitemid 350006946)
40. MacLeod M, Kwakkenbos MJ, Crawford A, et al. CD4 memory T-cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med. 2006;203(4):897-906.
41. Rodriguez-Pinto D, Moreno J. B-cells can prime naive CD4+ T-cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol. 2005;35(4):1097-1105. (Pubitemid 40542216)
42. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501-513. (Pubitemid 40216314)
43. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33. (Pubitemid 351650318)
44. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141(2):149-169. (Pubitemid 351406218)
45. Edwards JC, Cambridge G, Leandro MJ. B-cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol. 2006;20(5):915-928. (Pubitemid 44382384)
46. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358(9292):1511-1513. (Pubitemid 33055705)
47. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenousimmunoglobulin. Br J Haematol. 2009;146(1):120-122.
48. Diwakar L, Gorrie S, Richter A, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol. 2010;63(3):275-277.
49. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol. 2009;84(10):661-665.
50. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755-2762.
51. Stasi R, Pagano A, Stipa E, Amadori S, Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
52. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87(2):189-195. (Pubitemid 34160626)